
Psoriatic Arthritis (PsA) Treatment Pathway in Adults

Approved by Surrey & North West Sussex Area Prescribing Committee Feb 2019 (updated September 2019)



Notes to the pathway and agreed definitions:

Primary Failure – occurs when the response criteria (as defined within the NICE TA) is not fully met when response to treatment is assessed at the time interval defined within the NICE TA. **Move to the NEXT treatment line / mode of action** (if one is available)

Secondary Failure – occurs when the response to treatment (as defined within the NICE TA) is no longer met. Move to the NEXT treatment line / mode of action (if one is available)

Primary intolerance/adverse effects – An occurrence that causes discontinuation of treatment, due to inability to tolerate side-effects of that treatment that occurs <u>during</u> the initial time period defined by the NICE TA. **Use another option from the SAME treatment line.**

Secondary intolerance/adverse effects— An occurrence that causes discontinuation of treatment, due to inability to tolerate side effects of that treatment that occurs <u>after</u> the initial time period defined by the NICE TA. Move to the NEXT treatment line OR discuss at RN meeting.

Conception – if conception plans or pregnancy indicate a change of drug is advisable, it is agreed that this does <u>not</u> constitute a change in line of treatment. Please update Blueteq accordingly.

When guiding on patient choice, consider the following:

Patient considerations: device, level of dexterity, frequency, route, adherence to drug.

Clinical considerations: disease characteristics, concomitant medication, IG levels, co-morbidities, antibody status, serological status (acute phase), absolute/relative contra-indications, previous history of malignancy, mode of action of chosen drug.

Drug-specific considerations: Bearing the above in mind, choose most appropriate agent from table below for patient and if no clear indication for a specific agent then use the least expensive.

The most cost-effective drugs currently for 1st line use are biosimilar adalimumab and apremilast.

Drug	Mode of action	Below are specific circumstances that may suggest the use of a specific agent. With all biologics there may a generalised increased risk of infection. In specific circum- stances such as interstitial lung disease (ILD), careful assessment prior to treatment and respiratory opinion is advised regardless of chosen biologic.
***Apremilast +/- methotrexate	PDE4 inhibitor	ONLY routinely commissioned for use <u>BEFORE</u> other treatment options in this path-
TA 433		way. Not as clinically effective as the TNF alpha inhibitors. Taken orally therefore some patients may be willing to accept a certain level of re- duced effectiveness.
Adalimumab TA 199	TNF alpha inhibitor	Psoriasis (TA 146), Crohn's (TA 187), Ulcerative colitis (TA 329) Hidradenitis suppurativa (TA 392) Uveitis (Level II evidence) Women of child-bearing age (compatible with first and second trimester of pregnancy Dactylitis, Enthesitis, Nail psoriasis (Level III evidence)
Certolizumab +/- methotrexate TA 445	TNF alpha inhibitor	Women of child-bearing age (compatible with all three trimesters of pregnancy (low placental transfer) Dactylitis, Enthesitis, Nail psoriasis (Level III evidence)
Etanercept +/- methotrexate TA 199	TNF alpha inhibitor	Potential risk of TB Women planning a pregnancy in near future (shortest time of discontinuation prior to conception) Consider if potential serious infection risk Dactylitis, Enthesitis, Nail psoriasis (Level III evidence)
Golimumab +/- methotrexate TA 220	TNF alpha inhibitor	Consider if patient over 100kg (patient access to double dose) Needle phobia/compliance issues/patient convenience Ulcerative colitis (TA 329) Dactylitis, Enthesitis (Level III evidence), Nail psoriasis (Level I evidence)
Infliximab +/- methotrexate TA 199	TNF alpha inhibitor	Compliance issues/needle phobia / Severely impaired manual dexterity** Ulcerative colitis (TA 329 / 140), Psoriasis (TA 134) Uveitis (Level II evidence), Dactylitis, Enthesitis (Level III evidence), Nail psoriasis (Level I evidence) Women of child-bearing age (compatible until 16 weeks of pregnancy)
Ixekizumab +/- methotrexate TA 537	IL-17A inhibitor	Moderate to severe plaque psoriasis (TA 442) Needle phobia/compliance issues/patient convenience There is NO NICE TA for the use of IL-12 / IL-23 after IL-17A or vice versa
Secukinumab +/- methotrexate TA 445	IL-17A inhibitor	Needle phobia/compliance issues/patient convenience (monthly maintenance dosing) Moderate to severe plaque psoriasis (TA 350), Ankylosing spondylitis (spondyloarthritis) (TA 407). There is NO NICE TA for the use of IL-12 / IL-23 after IL-17A or vice versa
Ustekinumab +/- methotrexate TA 340	IL-12 / IL-23 inhibitor	Only routinely commissioned for use <u>AFTER</u> TNF alpha inhibitor (unless patient contra- indicated to TNF alpha therapy) (TA 340) Needle phobia/compliance issues/patient convenience (3 monthly dosing) Psoriasis (TA 180) Dactylitis, Enthesitis, Nail Psoriasis
***Tofacitinib with methotrexate TA543	JAK inhibitor	Only routinely commissioned in line with NICE TA i.e. after use of a TNF alpha inhibitor (primary or secondary failure) or if TNF alpha inhibitors are CI. Ulcerative Colitis (TA 547)

* monthly dosing, ** intravenous infusion (IV), *** oral dosing

Produced by: Surrey Rheumatology Network : March 2011 (updated Sept 2015, Nov 2016, March 2017, Jan 2019).

Takes into account NICE TA 199 / TA 433 / TA 445 / TA 220 / TA 537 / TA 340 / TA 445 / TA 543, Manchester Academic Health Science Centre (MAHSC) Harmonised biologics pathway for AS and PsA

Agreed Date: Surrey & North West Sussex APC (formerly PCN) May 2017, July 2017, Nov 2018, Feb 2019, September 2019 Review Date: Feb 2022